Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Self‐harm Measured by: clinicians Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes self‐harm Timing of outcome assessment: end of treatment (8 to 24… compared with placebo (very low certainty).
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Mood stabilisers may leads to lower attrition Timing of outcome assessment: end of treatment (32 days to… compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Deliberate self‐harm · patients with borderline personality disorder
1 finding from 1 review
Clinical remission · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in clinical remission compared with placebo or Control (low certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes CDAI <150 at 24 weeks compared with placebo or Control (very low certainty).
1 finding from 1 review
Fistula Closure short‐term · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell may leads to higher fistula Closure short‐term compared with placebo or Control (low certainty).
1 finding from 1 review
Fistula closure in long‐term · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell may leads to higher fistula closure in long‐term compared with placebo or Control (low certainty).
1 finding from 1 review
Total adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).
1 finding from 1 review
Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes withdrawal due to adverse events compared with placebo or Control (very low certainty).
1 finding from 1 review